What Ga-68 DOTANOC Targets
Ga-68 DOTANOC is a radioactive tracer that binds to somatostatin receptors, which are found on the surface of many neuroendocrine tumour (NET) cells. Somatostatin receptors are a family of proteins, and DOTANOC binds to several subtypes (particularly types 2, 3, and 5), giving it broad coverage across different NETs.
When the tracer is injected and a PET CT scan is performed, neuroendocrine tumour cells that express these receptors light up on the images. This provides a detailed map of where the tumour is located throughout the body.
Why Standard Scans May Not Be Enough for NETs
Neuroendocrine tumours are often small and can occur in locations that are difficult to evaluate with conventional CT or MRI alone. Some NETs are metabolically quiet, meaning they do not show increased glucose uptake on an FDG PET CT scan. Low-grade and well-differentiated NETs, which are the most common subtypes, fall into this category.
Ga-68 DOTANOC PET CT fills this gap. Because it targets the somatostatin receptors that these tumours express, it can detect NETs that would be missed by FDG-based imaging. It is generally more sensitive than CT or MRI for detecting small tumour deposits, particularly in the liver and lymph nodes.
When This Scan Is Ordered
Doctors order Ga-68 DOTANOC PET CT in several scenarios:
Diagnosis and staging: When a neuroendocrine tumour is suspected or confirmed, this scan helps determine the full extent of disease. It identifies the primary tumour and any metastatic deposits.
Treatment planning: The scan result directly influences treatment decisions. If the tumour shows strong somatostatin receptor expression, the patient may be a candidate for somatostatin analogue therapy (octreotide or lanreotide) or radioligand therapy (Lu-177 DOTATATE).
Monitoring: Follow-up scans can assess how the tumour is responding to treatment and whether new lesions have appeared.
Unknown primary: Sometimes neuroendocrine tumour metastases are found before the primary tumour has been identified. Ga-68 DOTANOC PET CT can help locate the primary site.
The Connection to Lu-177 DOTATATE Therapy
Ga-68 DOTANOC PET CT and Lu-177 DOTATATE therapy form a theranostic pair. The diagnostic scan confirms that the tumour cells express somatostatin receptors. If expression is strong, Lu-177 DOTATATE, which targets the same receptors and carries a therapeutic dose of radiation, can be used for treatment.
The strength of receptor expression on the diagnostic scan helps predict how well the therapy will reach the tumour, making it a key factor in treatment selection.
Talk to Your Specialist
If you have been diagnosed with a neuroendocrine tumour or are being investigated for one, discuss with your doctor whether a Ga-68 DOTANOC PET CT scan would be useful in your case. This scan provides specialised information that standard imaging may not capture, and the results have a direct bearing on treatment options.